Targeting $T_1$ and $T_2$ dual modality enhanced magnetic resonance imaging of tumor vascular endothelial cells based on peptides-conjugated manganese ferrite nanomicelles

Abstract: Tumor angiogenesis plays very important roles for tumorigenesis, tumor development, metastasis, and prognosis. Targeting $T_1$/$T_2$ dual modality magnetic resonance (MR) imaging of the tumor vascular endothelial cells (TVECs) with MR molecular probes can greatly improve diagnostic sensitivity and specificity, as well as helping to make an early diagnosis of tumor at the preclinical stage. In this study, a new $T_1$ and $T_2$ dual modality nanoprobe was successfully fabricated. The prepared nanoprobe comprise peptides CL 1555, poly(ε-caprolactone)-block-poly(ethylene glycol) amphiphilic copolymer shell, and dozens of manganese ferrite (MnFe$_2$O$_4$) nanoparticle core. The results showed that the hydrophobic MnFe$_2$O$_4$ nanoparticles were of uniform spheroidal appearance and narrow size distribution. Due to the self-assembled nanomicelles structure, the prepared probes were of high relaxivity of 281.7 mM$^{-1}$ s$^{-1}$, which was much higher than that of MnFe$_2$O$_4$ nanoparticles (67.5 mM$^{-1}$ s$^{-1}$). After being grafted with the targeted CD105 peptide CL 1555, the nanomicelles can combine TVECs specifically and make the labeled TVECs dark in $T_2$-weighted MR imaging. Our results demonstrate that CL-poly(ethylene glycol)-MnFe$_2$O$_4$ can conjugate TVECs and induce dark and bright contrast in MR imaging, and act as a novel molecular probe for $T_1$- and $T_2$-enhanced MR imaging of tumor angiogenesis.

Keywords: CL 1555, CL-PEG-MnFe$_2$O$_4$, TVECs, CD105, tumor angiogenesis

Introduction
Malignant tumor has been ranked the second leading cause of human mortality worldwide, accounting for 8.2 million cancer deaths in 2012. The lethality of cancer is mainly due to early metastasis and diagnosis at advanced stages. The common routes of metastasis of malignant tumors are hematogenous metastasis, lymphatic metastasis, implantation metastasis, and local infiltration, among which the blood metastases are the most important routes. In 1971, Folkman reported that the occurrence and development of a tumor were angiogenesis-dependent and tumor angiogenesis accelerated tumor growth and infiltration. So, the tumor blood vessels became the focus of cancer research, making vascular endothelial cells the leading targets for cancer research. In recent years, with the discovery of a series of markers of vascular endothelial cells, the study of tumor blood vessels has expanded into the molecular study.
level and the relationship between tumor blood vessels and tumor metastasis was confirmed through these molecular markers.\textsuperscript{5–8} Endoglin, also called CD105, is a moiety of the transforming growth factor-beta receptor complex and regulates angiogenesis by participating in signal transduction of the transforming growth factor-beta receptor. It has been reported that CD105 is overexpressed in neovascularization of regenerated, inflammatory, and tumor tissues and its expression is positively correlated with the cancer angiogenesis.\textsuperscript{7–9} Therefore, CD105 is an ideal biomarker for targeting tumor vascular endothelial cells (TVECs).

Magnetic resonance imaging (MRI) is one of the best noninvasive methods used in clinical medicine today because of its superb spatial resolution, soft-tissue contrast resolution, lack of radiation exposure, and multiparameter and multi-sequence imaging.\textsuperscript{10–12} However, MRI is less sensitive than positron emission tomography and fluorescence imaging, making it not suitable for small lesion monitoring or molecule tracing. The application of magnetic contrast agents (CAs) markedly enhances the sensitivity of MRI.\textsuperscript{13–15} Usually, MR CAs can be divided into two categories: one is positive CAs, which can mainly reduce longitudinal relaxation ($T_1$) time and induce hyperintensity in $T_1$-weighted imaging; the other is negative CAs which can mainly shorten transverse relaxation ($T_2$) time and provide negative contrast in $T_2$-weighted imaging.\textsuperscript{16} There have been many types of CAs available for clinical MRI, including gadolinium- or manganese-based chelates as $T_1$ CAs and iron oxide ($Fe_3O_4$)-based nanoparticles (NPs) as $T_2$ CAs.\textsuperscript{17–19} However, both kinds of CAs have limitations. Because of magnetic susceptibility artifacts and their positive or negative contrast effect, the tissues labeled with gadolinium-based complex or $Fe_3O_4$ NPs may not be clearly distinguishable from the hyperintensity or low level MR signal arising from adjacent tissues.\textsuperscript{20,21} Meanwhile, it has been reported that some gadolinium-based CAs can result in nephrogenic systemic fibrosis for patients with severe renal disease.\textsuperscript{22} Manganese ferrite ($MnFe_2O_4$) NPs have been proven to be of higher saturation magnetization and transverse relaxivity ($r_2$) than other ferrite NPs, including cobalt ferrite ($CoFe_2O_4$), $Fe_3O_4$, and nickel ferrite ($NiFe_2O_4$).\textsuperscript{23–25} Additionally, multiple $MnFe_2O_4$ NPs encapsulated inside one nanomicelle (NM) can result in much stronger $r_2$ than a single NP at the same metal concentration, making them excellent candidates for high sensitive $T_2$-enhanced MRI.\textsuperscript{26,27} The $MnFe_2O_4$ NPs within cells will be gradually broken down in lysosomes and then release paramagnetic Mn\textsuperscript{2+}. At the mean time, the size of $MnFe_2O_4$ NPs decreased correspondingly. The above two effects can significantly shorten the $T_1$ relaxation time of the surrounding protons and induce hyperintensity in $T_1$-weighted imaging.\textsuperscript{19,28–31} So, the $MnFe_2O_4$ NPs can act as both $T_1$ and $T_2$ CAs in MRI. As a negative CA, $MnFe_2O_4$ NPs can cause dark contrast in $T_2$ and $T_2^*$-weighted imaging (WI). Upon internalization by cells and localization in lysosomes, released Mn\textsuperscript{2+} ions and NPs with smaller size can act as strong $T_1$ MRI CAs, making the dark areas in $T_1/T_2^*$-WI bright in $T_1$-weighted imaging,\textsuperscript{30,32} to improve the accuracy of diagnosis of MRI greatly.

Bi\textsuperscript{33} identified a peptide with high binding affinity and selectivity toward CD105 and demonstrated that the selected peptide could act as a CD105 specific ligand. The peptide called CL 1555 (sequence: AHKHVHHPVRL) was selected from a phage displayed library.\textsuperscript{34} CL 1555 was condensed with only a dozen of amino acids, resulting in a simpler steric configuration, better diffusion and penetration in vivo, and less immunogenicity compared with anti-CD105 antibody. Because of small steric hindrance, the peptide had a high grafting rate when it was connected to the functional group on the surface of the NPs, which will improve the probe affinity, connective stability, and specificity with the targeted molecule.\textsuperscript{35} So, CL 1555 is an ideal ligand to CD105 for targeted diagnosis and therapy.

In previous studies, we conjugated anti-CD105 antibody with stabilized immunoliposome (SL)-encapsulated gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) and thiol-PEG-carboxyl-stabilized $Fe_3O_4$/Au NPs to evaluate tumor angiogenesis on $T_1$- or $T_2$-enhanced MRI, respectively.\textsuperscript{36,37} The results showed that CD105-Gd-SLs and hybrid-PEG-CD105 could be utilized to detect subcutaneous glioma and breast cancer angiogenesis in tumor-bearing rats. Based on the previous work, this research focuses on synthesizing and characterizing a molecular probe CL-poly(ethylene glycol) (PEG)-$MnFe_2O_4$ based on the CD105 specific ligand CL 1555 and $MnFe_2O_4$ NMs to detect tumor angiogenesis using $T_1$- and $T_2$-enhanced MRI.

**Materials and methods**

**Materials**

Iron acetylacetonate, manganese acetylacetonate, oleic acid, oleylamine, benzyl ether, hexane, ε-caprolactone, tetrahydrofuran (THF), N-(3-dimethylaminopropyl)-N-ethylacrylamide, N-hydroxysuccinimide, stannous octoate, tetramethylammonium hydroxide (TMAH), heparin, l-glutamine, reactive oxygen species (ROS) assay kit, and sodium pyruvate were all purchased from Sigma-Aldrich Co. (St Louis, MO, USA). PEG with a terminal hydroxyl and carboxylic acid functional groups (COOH-PEG-OH) was purchased from JenKem Technology (Beijing, People’s Republic of China). 1,2-Hexadecanediol was obtained from Republic of China). 1,2-Hexadecanediol was obtained from Republic of China). 1,2-Hexadecanediol was obtained from Republic of China). 1,2-Hexadecanediol was obtained from Republic of China). 1,2-Hexadecanediol was obtained from Republic of China). 1,2-Hexadecanediol was obtained from Republic of China).
TCI (Shanghai) Development Co., Ltd (Shanghai, People’s Republic of China). Medium 199, Roswell Park Memorial Institute 1640 medium, fetal bovine serum, penicillin/streptomycin, and nonessential amino acid were purchased from Hyclone, Logan, UT, USA. Count Kit-8 (CCK-8) was obtained from Beyotime Biotechnology Company, Beijing, People’s Republic of China. Endothelial cell growth supplement was purchased from Sciencell, CA, Carlsbad, USA. Six-well plates were obtained from Corning Incorporated, Corning, NY, USA.

Synthesis of MnFe$_2$O$_4$ NPs

According to a published procedure,$^{38}$ iron acrylate (2 mmol), manganese acrylate (1 mmol), 1,2-hexadecanediol (10 mmol), oleic acid (6 mmol), and oleylamine (6 mmol) were mixed in 20 mL benzyl ether under dry and deoxidized argon atmosphere. Then, the mixture was successively heated to 200°C for 2 hours and refluxed at 300°C for 1 hour. After cooling to room temperature, the mixture was treated with ethanol and then centrifuged several times. Finally, the product was dispersed in anhydrous hexane for storage. In order to transfer the prepared NPs into water, hydrophobic MnFe$_2$O$_4$ NPs were treated with TMAH.$^{39}$ Briefly, 10 mL of NP suspension in hexane was added into 20 mL of ethanol and the NPs were collected with a permanent magnet. After decanting the solvent, the NPs were redispersed in 25 mL of TMAH aqueous solution (10%, w/v) and sonicated for 10 minutes. After centrifugation, the hydrophobic surfactant (oleic acid/oleylamine) on the surface of NPs was replaced with TMAH, making them bear negative surface charges and be stable in water. Finally, the surface ligand-exchanged NPs (TMAH-MnFe$_2$O$_4$) were suspended in 10 mL of deionized water.

Synthesis of CL-PEG-MnFe$_2$O$_4$ NPs

Amphiphilic block copolymer poly(ε-caprolactone)-block-PEG-COOH (PCL-b-PEG-COOH) was synthesized using ε-caprolactone, COOH-PEG-OH, and stannous octoate by ring opening polymerization.$^{40}$ The resulting copolymers were dissolved in THF and precipitated in excess amount of diethyl ether. The precipitates were then dried in vacuum oven. The dried MnFe$_2$O$_4$ NPs and prepared copolymer were redispersed in THF with a mass ratio of 2:1. Afterwards, the ultrapure water was poured into the mixture under ultrasonication. The oil–water mixture was then dialyzed in a dialysis bag with a molecular weight cutoff of 14,000 overnight to remove the residual THF and the remaining products were PEG-b-PCL-MnFe$_2$O$_4$ NMs. CL 1555 was purchased from ChinaPeptides Co., Ltd (Shanghai, People’s Republic of China) and coupled to terminal carboxylic acid functional amphiphilic block copolymer PCL-b-PEG-COOH through N-(3-dimethylaminopropyl)-N-hexylacrylamide chemistry following a previous method.$^{40,41}$ Finally, the TVECs targeting nanoprobe CL-PEG-MnFe$_2$O$_4$ NMs were obtained.

NP characterization

The morphology, size, and size distribution of MnFe$_2$O$_4$ and PEG-b-PCL-MnFe$_2$O$_4$ were measured using transmission electron microscopy (TEM) (JEOL-2100F, JOEL, Tokyo, Japan). The diameter in dispersion and polydispersity index were determined through the dynamic light scattering technique (Nano zs90, Malvern Instruments, Malvern, UK). The Fe and Mn elemental contents of MnFe$_2$O$_4$ and PEG-b-PCL-MnFe$_2$O$_4$ were quantified by energy dispersive spectrometer analysis in TEM (JEOL-2100F) and inductive-coupled plasma optical emission spectrometer. The coercivity, magnetization, and hysteresis loop of MnFe$_2$O$_4$ were evaluated using vibrating sample magnetometer (ADE Technologies, Lowell, MA, USA). Serial metal (Fe + Mn) concentrations (0, 0.01, 0.02, 0.03, 0.04, 0.06, 0.08, 0.1, 0.2, 0.4, 0.6, and 0.8 mM) of both TMAH-MnFe$_2$O$_4$ and PEG-b-PCL-MnFe$_2$O$_4$ were scanned in a head coil using a 3.0 T clinical MR scanner (Signa HDx, GE healthcare, Little Chalfont, UK). The scanning parameters were as follows: matrix 256x256, field of view 16x16 cm, interlayer spacing 0.4 mm, fast spin echo (FSE) T$_2$-weighted imaging (repetition time [TR] 2000 ms and echo time [TE] 43.7 ms), gradient echo [GRE] T$_2$*WI (TR 400 ms, TE 12.0 ms, and flip angle 30°), and 16 echo T$_1$ mapping (TR 1025 ms and TE 2.4–60.5 ms). The r$_2$ was calculated through the curve fitting of the 1/T$_2$ relaxation time (s$^{-1}$) versus the concentration (mM). The region of interest was 5 mm$^2$.

Cells culture

Human umbilical vein endothelial cells (HUVECs) were routinely harvested by digesting human umbilical veins with type-I collagenase as previously described.$^{42}$ With approval from the Medical Ethics Committee of Xinqiao Hospital of Third Military Medical University and written patient consent, the human umbilical cords were obtained from the Department of Obstetrics and Gynecology of Xinqiao Hospital. The specificity and purity of the isolated cells were evaluated using immunofluorescence staining and flow cytometry. HUVECs were cultured in medium 199 supplemented with 20% fetal bovine serum, 1% endothelial cell growth supplement, 0.05 mg/mL of heparin, 2 mM of L-glutamine, and 100 U/mL of penicillin/streptomycin. The third to tenth passages were used for the following cocultivation experiments.
Human breast cancer cells MDA-MB-231 were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in Roswell Park Memorial Institute 1640 medium containing 10% fetal bovine serum, 1 mM sodium pyruvate, 1% nonessential amino acid, 2 mM of L-glutamine, and 100 U/mL of penicillin/streptomycin. All the cells were incubated in a humidified incubator (Thermo Fisher Scientific, Waltham, MA, USA) with 5% CO₂ at 37°C. To simulate the microenvironment of cancer, HUVECs were cocultured with MDA-MB-231 in a transwell coculture system (Merck Millipore, Billerica, MA, USA). HUVECs were seeded in transwell inserts with 0.1 µm pore at a 1:5 ratio to tumor cells and were added into 6-well plates with MDA-MB-231 cultured in them. HUVECs and MDA-MB-231 were all cultured overnight for adherence before cocultivation and maintained in cocultural system for a further 48 hours. The collected cells were called TVECs.

**Cytotoxicity analysis**

To analyze the biocompatibility of CL-PEG-MnFe₂O₄, we used a Cell Count Kit-8 (CCK-8) to test the cytotoxicity of CL-PEG-MnFe₂O₄ on TVECs in comparison with a molecular manganese agent. Briefly, cells were seeded in 96-well plates at a density of 5x10⁴ cells/well and cultured overnight. Then, fresh medium containing CL-PEG-MnFe₂O₄ with serial metal (Fe + Mn) concentrations (0, 0.01, 0.05, 0.09, 0.23, 0.45, 0.9, 1.8, and 4.5 mM) and MnCl₂ with serial Mn concentrations (0, 0.01, 0.05, 0.09, 0.23, 0.45, 0.9, 1.8, and 4.5 mM) was added to replace the previous medium and cultured overnight. Then, fresh medium containing CL-PEG-MnFe₂O₄ with serial metal (Fe + Mn) concentrations (0, 0.01, 0.05, 0.09, 0.23, 0.45, 0.9, 1.8, and 4.5 mM) and MnCl₂ with serial Mn concentrations (0, 0.01, 0.05, 0.09, 0.23, 0.45, 0.9, 1.8, and 4.5 mM) was added to replace the previous medium and incubated for a further 24 hours, respectively. Each concentration of the samples was repeated five times. Because the CCK-8 assay relies on the optical density of orange formazan and might be affected by the NPs, the medium containing CL-PEG-MnFe₂O₄ and MnCl₂ was displaced by the mixture containing 100 µL of fresh medium and 10 µL of 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium after incubation for corresponding time. Following 1.5 hours of coculture, the medium containing formazan was transferred into a new 96-well plate with a permanent magnet under the plate to minimize the influence of NPs on the absorbance. A spectral scanning multimode reader (Varioskan Flash, Thermo Scientific) was used to determine the optical density at a wavelength of 490 nm. In addition, for the cytotoxicity assessment of CL-PEG-MnFe₂O₄ on TVECs, the level of intracellular ROS was quantified using a ROS assay kit (Sigma-Aldrich Co.). TVECs were labeled with CL-PEG-MnFe₂O₄ of serial metal concentrations (0, 0.01, 0.05, 0.09, 0.23, 0.45, 0.9, 1.8, and 4.5 mM) for 24 hours. The labeled cells were then incubated with 2,7-dichlorofluorescin diacetate and the fluorescent intensity was measured by flow cytometry (MoFlo XDP, Beckman Coulter, Brea, CA, USA) with excitation and emission wavelengths of 488 and 525 nm, respectively.

**Labeling of TVECs**

To evaluate the targeted labeling efficiency of CL-PEG-MnFe₂O₄, the TVECs were cocultured with CL-PEG-MnFe₂O₄, PEG-b-PCL-MnFe₂O₄, and the mixture of CL-PEG-MnFe₂O₄ and CL 1555 peptides in a ratio of 1:100 (for competition binding experiment) at the same metal concentration of 0.09 mM for 2 hours. Cells incubated with cell medium without any NPs were used as blank control. Prussian blue staining and MRI were used to determine the location within the cells and the labeling rate. For Prussian blue staining, the labeled cells were fixed with 4% paraformaldehyde, incubated with Prussian blue staining solution (containing equal volumes of 2% hydrochloric acid and 2% potassium ferrocyanide) for 30 minutes and stained with neutral red solution for 10 minutes. The images were obtained using an inverted fluorescence microscope (DMIRB, Leica Microsystems, Wetzlar, Germany). For MRI, cells were harvested by trypsinization and resuspended in 0.5 mL of 1% agarose gel in Eppendorf tubes. All the cells were scanned in a head coil using a 3.0 T clinical MR scanner (Signa HDx) following the previous scanning parameters.

**Subculture of the labeled cells and their MRI**

The TVECs were seeded into cell culture flask with 25 cm² effective area at a density of 4x10⁴ cells/cm². After adherence, the cells were incubated with CL-PEG-MnFe₂O₄ with metal concentration of 0.18 mM for 2 hours. Then, the culture medium with NPs was replaced with fresh medium and the cells were incubated till 80% confluency was reached and tagged as passage one (P₁). Half of labeled TVECs of P₁ were passaged in a 1:2 ratio and tagged as passage two (P₂). The remaining cells were resuspended in 1% agarose gel and scanned in a head coil using a 3.0 T clinical MR scanner according to the parameters described in the section of NP characterization. Similarly, the labeled TVECs were continuously passaged to passage four and each passage was correspondingly tagged as P₃ and P₄ and each passage cell was treated similarly to P₁.

**Statistics**

All results were expressed as the mean ± standard deviation. Statistical analysis was carried out using SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). The statistical comparisons were performed using the Student’s t-test and one-way
analysis of variance; a $P$-value $<0.05$ indicated a significant difference.

**Results**

**TEM analysis**

MnFe$_2$O$_4$ NPs synthesized from thermal decomposition of iron acetylacetonate and manganese acetylacetonate in a 2:1 ratio were of spheroidal appearance and narrow size distribution (Figure 1A). The results from Image Pro Plus 6.0 showed that the average size was $7.6\pm1.0$ nm (Figure 1B), as counted with 300 NPs that were randomly selected. After being enveloped with amphiphilic block copolymer PEG-b-PCL, dozens of hydrophobic MnFe$_2$O$_4$ NPs assembled together (Figure 1C). The diameter of PEG-b-PCL-MnFe$_2$O$_4$ was $146.7\pm25.9$ nm according to the TEM photomicrograph (Figure 1D). Figure 2A and B show a high resolution TEM image of a single MnFe$_2$O$_4$ NP. The spacings between the lattice fringes were measured to be around $0.301$ and $0.257$ nm, which correspond to the planes of (220) and (311) of bulk MnFe$_2$O$_4$ very well. Moreover, the measured interplanar spacings based on the diffraction rings in the selected area electron diffraction (inset of Figure 1A) were perfectly in agreement with the respective hkl indexes of bulk MnFe$_2$O$_4$ from the Joint Committee on Powder Diffraction

![Figure 1](image_url)

**Notes:** MnFe$_2$O$_4$ NPs were of spheroidal appearance and narrow size distribution (A) and the average size was $7.6\pm1.0$ nm (B). The diameter of PEG-b-PCL-MnFe$_2$O$_4$ NMs was $146.7\pm25.9$ nm (C and D). Inset of (A) is SAED of MnFe$_2$O$_4$ NPs. Inset of (C) is an enlarged TEM of a single PEG-b-PCL-MnFe$_2$O$_4$ NM; magnification $>200,000$.

**Abbreviations:** NMs, nanomicelles; NPs, nanoparticles; PEG-b-PCL, polyethylene glycol-block-poly(ε-caprolactone); SAED, selected area electron diffraction; TEM, transmission electron microscopy.
Abbreviations:

and 

Notes:

Figure 3

the molar ratio of Fe and Mn in MnFe 

atomic ratio of Fe to Mn was around 2:1, agreeing well with 

meanwhile, the Cu signal is derived from the TEM grid. The 
cated the presence of Mn, Fe, and O in the NP (Figure 2C); 

spectrometer measurement. The Mn, Fe, and O peaks indi 

the nanocrystals was confirmed using the energy dispersive 

Standards (JCPDS) database, indicating that the synthetic 

NPs are MnFeO nanocrystals. The chemical composition of 

the nanocrystals was confirmed using the energy dispersive 
spectrometer measurement. The Mn, Fe, and O peaks indi 
cated the presence of Mn, Fe, and O in the NP (Figure 2C); 

meanwhile, the Cu signal is derived from the TEM grid. The 
atomic ratio of Fe to Mn was around 2:1, agreeing well with 
the molar ratio of Fe and Mn in MnFeO.

Dynamic light scattering and inductive-coupled plasma optical emission spectrometer measurement

According to the results of dynamic light scattering, the hydrodynamic diameter of MnFeO dispersed in hexane was 

10.3±1.2 nm (Figure 3A), which was slightly larger than the size measured by TEM. This might be due to the coating of oleic acid or oleylamine on the outer surface of the NP that could affect the light scattering while it could not be detected under the TEM. Similarly, because of the hydrodynamic size effect and electronic permeability of the PEG-b-PCL, the zeta sizes of PEG-b-PCL-MnFeO and CL-PEG-MnFeO were 162.6±28.9 nm (Figure 3B) and 183.4±26.5 nm (Figure 3C), which were larger than those obtained from TEM observations. Inductive-coupled plasma optical emission spectrometer analysis showed that Fe and Mn elemental contents of MnFeO were 363.5 and 167.9 mg/L, which matched the result of energy dispersive spectrometer analysis and revealed that the molar ratio of Fe and Mn of MnFeO was ~2:1, indicating that the prepared NPs were MnFeO.

Magnetization and T2 relaxivity

To understand the magnetic property of the prepared MnFeO NPs, 46.8 mg nanopowder was tested using a vibrating sample magnetometer. The magnetization rose nonlinearly with the increase of applied magnetic field (Figure 4A). The prepared NPs showed no remaining net magnetization in the absence of an external field, which indicated that the MnFeO NPs were superparamagnetic at 300 K. Under a powerful magnetic field, NPs will reach their saturation magnetization, which was 68.2 emu/g. Figure 5 shows that TMAH-MnFeO NPs and PEG-b-PCL-MnFeO NMs both exhibited a concentration-dependent signal drop in the GRE T2*WI and FSE T2-weighted imaging. Their signal
intensities decreased gradually with the increase of the metal ion concentration. However, PEG-b-PCL-MnFe$_2$O$_4$ NMs induced greater hypointensity at an identical concentration compared with TMAH-MnFe$_2$O$_4$ NPs. The linear fitting of concentration and $1/T_2$ showed that the $r_2$ of PEG-b-PCL-MnFe$_2$O$_4$ NMs was $281.7 \text{ mM}^{-1} \text{s}^{-1}$, which was ~4.2 times higher than that of TMAH-MnFe$_2$O$_4$ NPs ($67.5 \text{ mM}^{-1} \text{s}^{-1}$) (Figure 4B).

**Figure 4** Hysteresis loop and $T_2$ relaxivity.

**Notes:** The hysteresis loop of MnFe$_2$O$_4$ NPs (A) showed that the magnetization rose nonlinearly with the increase of applied magnetic field and no remaining net magnetization in the absence of an external field, indicating that the MnFe$_2$O$_4$ NPs are superparamagnetic at 300 K. The MnFe$_2$O$_4$ NPs saturation magnetization was $68.2 \text{ emu/g}$ (A). The linear fitting of concentration and $1/T_2$ showed that the $r_2$ of PEG-b-PCL-MnFe$_2$O$_4$ NMs was $281.7 \text{ mM}^{-1} \text{s}^{-1}$, which was ~4.2 times higher than that of TMAH-MnFe$_2$O$_4$ NPs ($67.5 \text{ mM}^{-1} \text{s}^{-1}$) (B).

**Abbreviations:** NMs, nanomicelles; NPs, nanoparticles; PEG-b-PCL, polyethylene glycol-block-poly(ε-caprolactone); $r_2$, transverse relaxivity; $T_2$, transverse relaxation time; TMAH, tetramethylammonium hydroxide.

**Cytotoxicity analysis**

The relative cell viability (RCV) of each treatment group to control group was used to determine the cytotoxicity of CL-PEG-MnFe$_2$O$_4$ and MnCl$_2$ with different concentrations on TVECs. Figure 6 shows that the RCV of TVECs labeled with CL-PEG-MnFe$_2$O$_4$ within 0.9 mM decreased only 7%–9% compared to controls. As the concentration increased, the RCV decreased correspondingly, and a decrease of ~19%

**Figure 5** MRI of MnFe$_2$O$_4$, TMAH-MnFe$_2$O$_4$ NPs and PEG-b-PCL-MnFe$_2$O$_4$ NMs.

**Notes:** TMAH-MnFe$_2$O$_4$ NPs and PEG-b-PCL-MnFe$_2$O$_4$ NMs both exhibited a concentration-dependent signal drop in the GRE $T_1$WI and FSE $T_2$WI. The signal intensity decreased gradually with the increase of the metal ions concentration, while NMs induced greater hypointensity at an identical concentration compared with NPs.

**Abbreviations:** MRI, magnetic resonance imaging; NMs, nanomicelles; NPs, nanoparticles; PEG-b-PCL, polyethylene glycol-block-poly(ε-caprolactone); TMAH, tetramethylammonium hydroxide; $T_1$WI, $T_1$-weighted imaging; GRE, gradient echo; FSE, fast spin echo.
in viability of TVECs incubated with 4.5 mM CL-PEG-MnFeO$_4$ solution was measured. On the contrary, a notable decrease of ~15% in viability was observed in TVECs incubated with only 0.05 mM MnCl$_2$ solution. When the TVECs were incubated with MnCl$_2$ solution as high as 4.5 mM, there were only 36.2% cells that survived. The CCK-8 results demonstrated that the CL-PEG-MnFeO$_4$ showed no acute toxicity to TVECs even at high concentrations, indicating their much better biocompatibility than molecular manganese agents. The ROS level of TVECs labeled with 0, 0.05, 0.23, 0.45, 0.9, and 4.5 mM CL-PEG-MnFeO$_4$ solutions are shown in Figure 7. It was shown that the induction of ROS depended on the concentration and an insignificant ROS level elevation was detected in the cells exposed to CL-PEG-MnFeO$_4$ within 0.9 mM. However, a 3.18% higher intracellular ROS level was measured in the cells incubated with 4.5 mM CL-PEG-MnFeO$_4$ solution compared with 0.9 mM CL-PEG-MnFeO$_4$.

**Labeling of TVECs with CL-PEG-MnFeO$_4$**

As the ferric ferrocyanide, which is a kind of dark blue pigment (also called Prussian blue), can be produced through the reaction of iron with potassium ferrocyanide within the acidic solution, the uptake of the CL-PEG-MnFeO$_4$, PEG-b-PCL-MnFeO$_4$, and the mixture of CL-PEG-MnFeO$_4$ and CL 1555 peptides can be observed under optical microscope after Prussian blue staining. Figure 8A–D are the results

![Graph](https://example.com/graph.png)
of Prussian blue staining of control group (Figure 8A) and TVECs labeled with CL-PEG-MnFe$_2$O$_4$ (Figure 8B), PEG-b-PCL-MnFe$_2$O$_4$ (Figure 8C) and the mixture of CL-PEG-MnFe$_2$O$_4$ and CL 1555 peptides (Figure 8D), which clearly shows a higher uptake of CL-PEG-MnFe$_2$O$_4$ than PEG-b-PCL-MnFe$_2$O$_4$ into TVECs. Blocking CD105 with the free CL 1555 peptides effectively reduced the amount of blue granules in the cytoplasm of TVECs, indicating that the internalization of CL-PEG-MnFe$_2$O$_4$ was specifically mediated by CL 1555 peptides. Figure 8E–H shows the MR images of the four groups of cells. Compared with the control, the cells cocultured with CL-PEG-MnFe$_2$O$_4$ showed a noticeable signal intensity drop and its T$_2$ relaxation time was 38.3±3.5 ms. However, the cells treated with PEG-b-PCL-MnFe$_2$O$_4$ and the mixture of CL-PEG-MnFe$_2$O$_4$ and CL 1555 peptides showed a similar signal intensity and T$_2$ relaxation time to the control.

**Subculture of the labeled cells and their MRI**

The TVECs labeled with CL-PEG-MnFe$_2$O$_4$ were subcultured from P$_1$ to P$_4$, and each generation was evaluated with a 3.0 T MRI system. As shown in Figure 9, the signal intensity from P$_1$ to P$_4$ in T$_1$-weighted images gradually increased and P$_4$ had almost equal signal intensity with control group. However, the signal intensity firstly increased and then decreased in T$_2$-weighted images. The labeled cells of P$_1$ presented low signal intensity similar to the control and those of P$_2$, P$_3$, and P$_4$ were hyper-intense. The T$_2$ relaxation time from P$_1$ to P$_4$ decreased firstly and then increased back accordingly (Figure 9).

**Discussion**

Angiogenesis, the formation of new blood vessels, is a requirement for tumor growth and metastasis.$^{3,4,43}$ Moreover, the tumor microvascular density was positively correlated with the trend of tumor metastasis and high microvascular density always leads to poor prognosis.$^{44,45}$ Commonly, the angiogenesis is estimated by histopathological examination. However, histopathological examination for angiogenesis does not demonstrate functionality within the vessels sampled and is inherent invasive and suffers from sampling bias.$^{46,47}$ Molecular imaging targeting vascular endothelial cells can offer this in a noninvasive way.$^{46,48-50}$ Due to a relatively good spatial resolution, good soft-tissue contrast, absence of ionizing radiation, and limited side effects, MRI

**Figure 8** In vitro labeling of TVECs with CL-PEG-MnFe$_2$O$_4$.

**Notes:** Prussian blue staining (200x) of control group (A), TVECs labeled with CL-PEG-MnFe$_2$O$_4$ (B), PEG-b-PCL-MnFe$_2$O$_4$ (C) and the mixture of CL-PEG-MnFe$_2$O$_4$ and CL 1555 peptides (D). It showed that the uptake of CL-PEG-MnFe$_2$O$_4$ was high, while few PEG-b-PCL-MnFe$_2$O$_4$ was engulfed into TVECs. Blocking CD105 with the free CL 1555 peptides also effectively reduced the amount of blue granules in the cytoplasm of TVECs. (E–H) showed the T2-weighted MR images of the four groups of cells. Correspondingly, the cells co-cultured with CL-PEG-MnFe$_2$O$_4$ (F) showed a more noticeable signal intensity drop than that with PEG-b-PCL-MnFe$_2$O$_4$ (G) and blocking with the free CL 1555 peptides (H).

**Abbreviations:** MR, magnetic resonance; PEG-b-PCL, polyethylene glycol-block-poly(ε-caprolactone); TVECs, tumor vascular endothelial cells.
has been proposed to be a good candidate for angiogenesis imaging.\textsuperscript{51–53} Endoglin, also called CD105, is a 180 kDa transmembrane protein and consists of a homodimer with disulfide links, and it has been found that its expression is usually low in resting endothelial cells and becomes highly expressed once neoangiogenesis begins.\textsuperscript{7,9,54} The important role that CD105 plays in tumor angiogenesis makes it an ideal candidate for tumor targeting imaging. In previous studies, we conjugated anti-CD105 antibody with SL-encapsulated Gd-DTPA and thiol-PEG-carboxyl-stabilized Fe\textsubscript{3}O\textsubscript{4}/Au NPs to evaluate tumor angiogenesis on T\textsubscript{1}- or T\textsubscript{2}-enhanced MRI, respectively.\textsuperscript{36,37} The results showed that CD105-Gd-SLs and hybrid-PEG-CD105 could be utilized to detect subcutaneous glioma and breast cancer angiogenesis in tumor-bearing rats. However, because of the larger molecular weight of anti-CD105 antibody, the probes have low connection efficiency and consequently have not enough affinity for the targeted TVECs. In order to improve the affinity of the probes, we employed a peptide – CL 1555 – which consisted of only 12 amino acids as the targeting molecule in the present study. CL 1555 was selected from a phage displayed library and was demonstrated to be of high affinity and selectivity toward CD105.\textsuperscript{33,34} Compared with anti-CD105 antibody, CL 1555 had a lower molecular weight and much smaller steric hindrance, resulting in a high grafting rate on the surface of the NMs. The results of our study showed that compared with PEG-MnFe\textsubscript{2}O\textsubscript{4}, CL-PEG-MnFe\textsubscript{2}O\textsubscript{4} binds to the surface of TVECs much better and markedly shortens T\textsubscript{2} of the labeled TVECs in T\textsubscript{2}-weighted images. In a competition binding experiment, the binding of CL-PEG-MnFe\textsubscript{2}O\textsubscript{4} and TVECs was blocked by free CL 1555 peptides, which revealed that the immobilization CL-PEG-MnFe\textsubscript{2}O\textsubscript{4} on the surface of TVECs was mediated by CL 1555. So, it was undoubtedly confirmed that CL 1555 was an ideal ligand to CD105 for targeted diagnosis and therapy.

Because of good biocompatibility, superparamagnetic Fe\textsubscript{3}O\textsubscript{4} NPs have been widely used as a negative CA for enhanced MRI.\textsuperscript{37,55,56} However, the r\textsubscript{2} of nanoscale Fe\textsubscript{3}O\textsubscript{4} was low and not enough for cell imaging and neovessel visualization in the early stage. MnFe\textsubscript{2}O\textsubscript{4} NPs have been proven to be of a higher saturation magnetization (M\textsubscript{p}) and r\textsubscript{2} than other ferrite NPs, including CoFe\textsubscript{2}O\textsubscript{4}, Fe\textsubscript{3}O\textsubscript{4}, and NiFe\textsubscript{2}O\textsubscript{4}.\textsuperscript{1,7,17} Lee et al\textsuperscript{25} fabricated a series of ferrite NPs, including CoFe\textsubscript{2}O\textsubscript{4}, Fe\textsubscript{3}O\textsubscript{4}, MnFe\textsubscript{2}O\textsubscript{4}, and NiFe\textsubscript{2}O\textsubscript{4}, and investigated their magnetic properties. They found that these ferrite NPs with a size of 12 nm all showed superparamagnetism. However, these NPs with an identical size have different M\textsubscript{p} and MnFe\textsubscript{2}O\textsubscript{4} exhibited a much higher M\textsubscript{p} than CoFe\textsubscript{2}O\textsubscript{4}, Fe\textsubscript{3}O\textsubscript{4}, and NiFe\textsubscript{2}O\textsubscript{4}. So, we employed MnFe\textsubscript{2}O\textsubscript{4} NPs as CAs for TVECs MR molecular imaging in the present study in order to improve the sensitivity of imaging. Besides the M\textsubscript{p}, the particle size can also influence the r\textsubscript{2} value. It has been reported that a different relation between r\textsubscript{2} value and particle size follows when the size is within different regimes. When the particles are small, the diffusional motion of water molecules surrounding these NPs is fast enough to average out the magnetic fields induced by these magnetic NPs. This regime is termed as motional averaging and the r\textsubscript{2} value is proportional to M\textsubscript{p} \tau\textsubscript{d}, where \tau\textsubscript{d} signifies the duration when water protons are under the influence of a magnetic NP and is proportional to r\textsuperscript{2}/D (D is the diffusion coefficient of water protons). Because \tau\textsubscript{d} increases with the increase of particle size, the averaging effect diminishes and the magnetic NPs appear as randomly distributed and stationary objects to water protons. In this regime, called static dephasing, the r\textsubscript{2} value is only proportional to M\textsubscript{p}. So, increasing the size of individual particle can enhance the r\textsubscript{2} value by motional averaging relaxation.\textsuperscript{17,26,58–61} However, this approach often posed technical difficulties because further increasing the size of the single NP will transfer the magnetic NPs from superparamagnetic to becoming ferromagnetic or ferrimagnetic. Then, the large, single core magnetic NPs will tend to aggregation in suspension because of the magnetic force between each other. An alternative route is to embed multiple magnetic NPs into a single multicore micelle.\textsuperscript{27,62–64} When the NPs aggregate, the size of the single multicore micelle will be increased into static dephasing regime and their r\textsubscript{2} value will be further increased through the static dephasing relaxation mechanism. In this work, we first synthesized the hydrophobic MnFe\textsubscript{2}O\textsubscript{4} NPs with a size of ~7.5 nm, which was in the regime of motional averaging. The M\textsubscript{p} of the prepared NPs was 68.2 emu/g. Afterward, we transformed the MnFe\textsubscript{2}O\textsubscript{4} NPs from hydrophobic to hydrophilic using amphiphilic block copolymer PEG-b-PCL. The MnFe\textsubscript{2}O\textsubscript{4} NPs modified with PEG-b-PCL then self-assembled into clusters and their size increased to ~146.7 nm, which was in the regime of static dephasing. After linear fitting of concentration and 1/T\textsubscript{2}, we found that the clusters consisting of dozens of MnFe\textsubscript{2}O\textsubscript{4} NPs were of much higher r\textsuperscript{2} of 281.7 mM\textsuperscript{-1} (Mn + Fe) s\textsuperscript{-1} than that of single NPs (67.5 mM\textsuperscript{-1} s\textsuperscript{-1}).

Because these nanoprobe were fabricated for biomedical application, we must evaluate their cytotoxicity first. The in vitro cytotoxicity of CL-PEG-MnFe\textsubscript{2}O\textsubscript{4} NMs toward TVECs was evaluated using CCK-8 analysis in comparison with molecular manganese agents. The results showed that the viability of TVECs labeled with CL-PEG-MnFe\textsubscript{2}O\textsubscript{4} within 0.9 mM decreased only 7%–9% compared to controls.
As the concentration increased, the RCV decreased correspondingly, and a decrease of ~19% in viability of TVECs incubated with 4.5 mM CL-PEG-MnFe$_2$O$_4$ solution was measured. On the contrary, a notable decrease of ~15% in viability was observed in TVECs incubated with only 0.05 mM MnCl$_2$ solution. When the TVECs were incubated with MnCl$_2$ solution as high as 4.5 mM, there were only 36.2% cells that survived. So, a conclusion can be easily drawn that the CL-PEG-MnFe$_2$O$_4$ showed no acute toxicity to TVECs even at relatively high concentrations, indicating their much better biocompatibility than MnCl$_2$. Several factors may contribute to the low cytotoxicity of CL-PEG-MnFe$_2$O$_4$ NMs. It has been demonstrated that several factors are responsible for the cytotoxicity of NPs, including ROS production and toxic ion leaching. The ROS induction has been posted as one of the main explanations for these toxic effects and induces various deleterious effects, including cell membrane damage, DNA and cytoskeleton injury, autophagy, and apoptosis. Here, the results of ROS assay depicted that an insignificant ROS level elevation was detected in the cells exposed to CL-PEG-MnFe$_2$O$_4$ within 0.9 mM and only a 3.18% higher intracellular ROS level was measured in the cells incubated with 4.5 mM CL-PEG-MnFe$_2$O$_4$ solution compared with that incubated with 0.9 mM CL-PEG-MnFe$_2$O$_4$, which might explain the CCK-8 results well. Moreover, the ferrite magnetic NPs have been proven to have intrinsic peroxidase-like activity, which can decrease the amount of intracellular H$_2$O$_2$ to promote cell proliferation. Regarding the ion leaching, in contrast to MnCl$_2$ solution, Mn ions leaching from Mn-based NPs have been demonstrated to be slower and Mn-based NPs showed no significant toxic effects on cells at a very high dosage of 200 µg/mL in some previous studies. Actually, to avoid high toxicity of Mn, some researchers employed Mn-based NPs as a sustained release delivery of Mn ions for neuroimaging instead of MnCl$_2$ solution.

Because of clearance and degradation of NPs from the labeled cells, it was reasonable that the signal intensity from P$_2$ to P$_1$ in T$_1$-weighted MR images gradually increased. However, it was very interesting that the signal intensity of these cells firstly increased and then decreased in T$_1$-weighted MR images. We hypothesized that T$_1$ enhancement of the labeled cells resulted from the divalent manganese ions and the smaller size MnFe$_2$O$_4$ NPs. It has been observed that the internalized nano- and microparticles are exclusively located within endosomes and finally in the lysosomes. Due to the abundance of proteolytic enzymes, chelating agents, and an acidic environment, the internalized particles will finally be degraded. For MnFe$_2$O$_4$ NPs, they were dissolved gradually and metallic ions Mn$^{2+}$ and Fe$^{3+}$ slowly released. Divalent manganese ions have five unpaired electrons and are paramagnetic, which have been regarded as strong T$_1$ MRI CA. Additionally, the reduction of NP size accompanied with the degradation of MnFe$_2$O$_4$ may also contribute to the high signal intensity of P$_2$ in T$_1$-weighted MR images. It is known that the surface atom ratio is inversely proportional to the particle size and large particles exhibit lower surface Mn$^{2+}$ ratio, leading to a small longitudinal relaxivity. When the internalized MnFe$_2$O$_4$ was degraded, its size decreased gradually. Accordingly, the surface Mn$^{2+}$ ratio of MnFe$_2$O$_4$ increased rapidly, resulting in a continuous growth of longitudinal relaxivity. When the size is 2.2 nm, the longitudinal relaxivity of MnFe$_2$O$_4$ is 6.61 mM$^{-1}$ s$^{-1}$, which is higher than that of the clinically used Gd-DTPA agent ($r_T=4.8$ mM$^{-1}$ s$^{-1}$).

**Conclusion**

In this study, we have successfully prepared an angiogenesis-targeting nanoprobe of high sensitivity for T$_1$ and T$_2$ MRI. The nanoprobe consists of MnFe$_2$O$_4$ NMs, which act as an MRI CA, and a peptide named CL 1555 for active targeting. These nanoprobes could specifically target TVECs with CD105 expression. The labeled TVECs could be imaged in T$_2$-weighted MRI and also in T$_1$-weighted MRI with the passage of labeled cells and the degradation of the internalized NPs. Based on these results, the prepared CL-PEG-MnFe$_2$O$_4$ nanoprobe could act as a promising CA for early detection of tumor angiogenesis using targeting TVECs and T$_2$-enhanced MRI.

**Acknowledgments**

We are very grateful to the National Natural Science Foundation of China (81401466 and 81501521) and General project of the frontier and application basic research plan of Chongqing (cstc2015jcylA1338) for financial support.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015;65(2):87–108.
2. Morgan-Parkes JH. Metastases: mechanisms, pathways, and cascades. *AJR Am J Roentgenol*. 1995;164(5):1075–1082.
3. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. *Biochim Biophys Acta*. 1990;1032(1):89–118.
4. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. *J Exp Med*. 1971;133(2):275–288.
5. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. *FASEB J*. 2004;18(2):338–340.
6. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin αβ₃ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. *Cell*. 1994;79(4):1157–1164.

7. Fonseca A, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenic blood vessels. *Oncogene*. 2003;22(42):6557–6563.

8. Seon BK. Expression of endoglin (CD105) in tumor blood vessels. *Int J Cancer*. 2002;99(2):310–311.

9. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. *FASEB J*. 2003;17(9):984–992.

10. Edelman RR, Warach S. Magnetic resonance imaging. *Adv Mater*. 2001;13(2):316–333.

11. Satoh Y, Ichikawa T, Motosugi U, et al. Diagnosis of peritoneal dissemination: comparison of ⁹⁹mTc-FDG PET/CT, diffusion-weighted MRI, and contrast-enhanced MDCT. *Am J Roentgenol*. 2011;196(2):447–453.

12. Thompson WO, Thaete FL, Fu FH, Dye SF. Tibial meniscal dynamics using three-dimensional reconstruction of magnetic resonance images. *Am J Sports Med*. 1991;19(3):210–216.

13. Weissleder R, Mahmood U. Molecular imaging I. *Radiology*. 2001;219(2):316–333.

14. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenic blood vessels. *Onco gene*. 2003;22(42):6557–6563.

15. Pichler BJ, Kolb A, Nägele T, Schlemmer H-P. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. *J Nucl Med*. 2010;51(3):333–336.

16. Thompson WO, Thaete FL, Fu FH, Dye SF. Tibial meniscal dynamics using three-dimensional reconstruction of magnetic resonance images. *Am J Sports Med*. 1991;19(3):210–216.

17. Tromsdorf UI, Bigall NC, Kaul MG, et al. Size and surface effects on assemblies potentiate magnetic properties of biomagnetic nanoparticles. *Adv Drug Deliv Rev*. 2010;62(8):739–749.

18. Edelman RR, Warach S. Magnetic resonance imaging. *Adv Mater*. 2001;13(2):316–333.

19. Satoh Y, Ichikawa T, Motosugi U, et al. Diagnosis of peritoneal dissemination: comparison of ⁹⁹mTc-FDG PET/CT, diffusion-weighted MRI, and contrast-enhanced MDCT. *Am J Roentgenol*. 2011;196(2):447–453.

20. Hu B, Dai F, Fan Z, Ma G, Tang Q, Zhang X. Nanotheranostics: Congo Red/Rutin/MNPs with enhanced magnetic resonance imaging and H₂O₂-responsive therapy of Alzheimer’s disease in APPsw/PS1ΔE9 transgenic mice. *Adv Mater*. 2015;27(37):5499–5505.

21. Gerald CF, Laurent S. Classification and basic properties of contrast agents for magnetic resonance imaging. *Contrast Media Mol Imaging*. 2009;4(1):1–23.

22. Tromsdorf UI, Bigall NC, Kaul MG, et al. Size and surface effects on assemblies potentiate magnetic properties of biomagnetic nanoparticles. *Adv Drug Deliv Rev*. 2010;62(8):739–749.

23. Edelman RR, Warach S. Magnetic resonance imaging. *Adv Mater*. 2001;13(2):316–333.

24. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenic blood vessels. *Onco gene*. 2003;22(42):6557–6563.

25. Pichler BJ, Kolb A, Nägele T, Schlemmer H-P. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. *J Nucl Med*. 2010;51(3):333–336.

26. Thompson WO, Thaete FL, Fu FH, Dye SF. Tibial meniscal dynamics using three-dimensional reconstruction of magnetic resonance images. *Am J Sports Med*. 1991;19(3):210–216.

27. Weissleder R, Mahmood U. Molecular imaging I. *Radiology*. 2001;219(2):316–333.

28. Song Q, Zhang ZJ. Controlled synthesis and magnetic properties of biomagnetic nanoparticles. *Adv Mater*. 2011;23(41):4793–4797.

29. Niu D, Luo X, Li Y, Liu X, Wang X, Shi J. Manganese-loaded dual-mesoporous silica spheres for efficient T₁- and T₂-weighted dual mode magnetic resonance imaging. *ACS Appl Mater Interfaces*. 2013;5(20):9942–9948.

30. Li Z, Wang SX, Sun Q, et al. Ultrasmall manganese ferrite nanoparticles as positive contrast agent for magnetic resonance imaging. *Adv Healthc Mater*. 2013;2(7):958–964.

31. Shaprio EM, Koretsky AP. Convertible magnetic contrast for molecular and cellular MRI. *Magn Reson Med*. 2008;60(2):265–269.

32. Chen W, Lu F, Chen CC, et al. Manganese-enhanced MRI of rat brain based on slow cerebral delivery of manganese(II) with silica-encapsulated MnFe₂O₄ nanoparticles. *NMR Biomed*. 2013;26(9):1176–1185.

33. Chen F-Y, Gu Z-J, Wan H-P, Xu X-Z, Tang Q. Manganese nanosystem for new generation of MRI contrast agent. *Rev Nanosci Nanotechnol*. 2015;4(2):81–91.

34. Bi X, Liang Z, Shi L. Determination of functional affinity of rEndoglin conjugated epitope. *J Third Mil Med Univ*. 2007;29(8):685–687.

35. Bi X, Liang Z, Shi L. Screening and function analysis of targeted short binding peptides of endoglin. *J Chongming Medical Univ*. 2007;3(3):232–235.

36. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. *Adv Drug Deliv Rev*. 2008;60(1):1307–1315.

37. Zhang D, Feng XY, Henning TD, et al. MR imaging of tumor angiogenesis using sterically stabilized Gd-DTPA liposomes targeted to CD105. *Eur J Radiol*. 2009;70(1):180–189.

38. Zhang S, Gong M, Zhang D, Yang H, Gao F, Zou L. Thiol-PEG-carboxyl-stabilized Fe₃O₄/Au nanoparticles targeted to CD105: Synthesis, characterization and application in MR imaging of tumor angiogenesis. *Eur J Radiol*. 2014;83(7):1190–1198.

39. Sun S, Zeng H, Robinson DB, et al. Monodisperse MFe₂O₃ (M = Fe, Co, Mn) nanoparticles. *J Am Chem Soc*. 2004;126(1):273–279.

40. Lim J, Eggeman A, Lanni F, Tilton RD, Majetich SA. Synthesis and single-particle optical detection of low-polydispersity plasmonic-superparamagnetic nanoparticles. *Adv Mater*. 2008;20(9):1721–1726.

41. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. *Cancer Res*. 2004;64(21):7668–7672.

42. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. *Proc Natl Acad Sci U S A*. 2006;103(16):6315–6320.

43. Gong M, Yang H, Zhang S, et al. Superparamagnetic core/shell Gold-Mag nanoparticles: size-, concentration- and time-dependent cellular nanotoxicity on human umbilical vein endothelial cells and the suitable conditions for magnetic resonance imaging. *J Nanobiotechnology*. 2015;13:24.

44. O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. *Cell*. 1997;88(2):277–285.

45. Jackson A, Kassner A, Annesley-Williams D, Reid H, Zhu X-P, Li K-L. Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade. *Am J Neuroradiol*. 2002;23(1):7–14.

46. Strohmeier D, Rissing C, Strauss F, Bauerfeind A, Kaufmann O, Loeung S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. *Prostate*. 2000;42(1):26–33.

47. Barrett T, Kobayashi H, Brechbiel M, Choyke PL. Macromolecular MRI contrast agents for imaging tumor angiogenesis. *Eur J Radiol*. 2006;60(3):353–366.

48. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. *J Magn Reson Imaging*. 2007;26(2):235–249.

49. Samei E, Saunders RS, Badea CT, et al. Micro-CT imaging of breast tumors in rodents using a liposomal, nanoparticle contrast agent. *Int J Nanomedicine*. 2009;4:277–282.
49. Liu Y, Yang Y, Zhang C. A concise review of magnetic resonance molecular imaging of tumor angiogenesis by targeting integrin αβ₃ with magnetic probes. *Int J Nanomedicine*. 2013;8:1083–1093.
50. Key J, Leary JF. Nanoparticles for multimodal in vivo imaging in nanomedicine. *Int J Nanomedicine*. 2014;9:711–726.
51. Wong EC. Vessel-encoded arterial spin-labeling using pseudocontinuous tagging. *Magn Reson Med*. 2007;58(6):1086–1091.
52. Li SP, Padhani AR, Makris A. Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment. *J Natl Cancer Inst Monogr*. 2010;2011(43):103–107.
53. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. *NMR Biomed*. 2002;15(2):154–163.
54. Clara CA, Marie SK, de Almeida JR, et al. Angiogenesis and expression of PDGF-C, VEGF, CD105 and HIF-1α in human glioblastoma. *Neuropathology*. 2014;34(4):343–352.
55. Xie J, Xu C, Kohler N, Hou Y, Sun S. Controlled PEGylation of monodisperse Fe₃O₄ nanoparticles for reduced non-specific uptake by macrophage cells. *Adv Mater*. 2007;19(20):3163–3166.
56. Ling D, Lee N, Hyeon T. Chemical synthesis and assembly of uniformly sized iron oxide nanoparticles for medical applications. *Acc Chem Res*. 2015;48(5):1276–1285.
57. Mazario E, Sánchez-Marcos J, Menéndez N, et al. High specific absorption rate and transverse relaxivity effects in manganese ferrite nanoparticles obtained by an electrochemical route. *J Phys Chem C*. 2015;119(12):6828–6834.
58. Chouly C, Pouliquen D, Lucet I, Jeune J, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. *J Microencapsul*. 1996;13(3):245–255.
59. Duan H, Kuang M, Wang X, Wang YA, Mao H, Nie S. Reexamining the effects of particle size and surface chemistry on the magnetic properties of iron oxide nanocrystals: new insights into spin disorder and proton relaxivity. *J Phys Chem C*. 2008;112(22):8127–8131.
60. Yablonskiy DA, Haacke EM. Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. *Magn Reson Med*. 1994;32(6):749–763.
61. Brooks RA, T. Shortening by strongly magnetized spheres: A chemical exchange model. *Magn Reson Med*. 2002;47(2):388–391.
62. Lu J, Ma S, Sun J, et al. Manganese ferrite nanoparticle micellar nanocomposites as MRI contrast agent for liver imaging. *Biomaterials*. 2009;30(15):2919–2928.
63. Ge J, Hu Y, Biasini M, Beyermann WP, Yin Y. Superparamagnetic magnetite colloidal nanocrystal clusters. *Angew Chem Int Ed Engl*. 2007;46(23):4342–4345.
64. Roca AG, Veintemillas-Verdaguer S, Port M, Robic C, Serna CJ, Morales MP. Effect of nanoparticle and aggregate size on the relaxometric properties of MR contrast agents based on high quality magnetite nanoparticles. *J Phys Chem B*. 2009;113(19):7033–7039.
65. Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. *Science*. 2006;311(5761):622–627.
66. Soenen SJ, Manshian B, Montenegro JM, et al. Cytotoxic effects of gold nanoparticles: a multiparametric study. *ACS Nano*. 2012;6(7):5767–5783.
67. Arbab AS, Wilson LB, Ashari P, Jordan EK, Lewis BK, Frank JA. A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. *NMR Biomed*. 2005;18(6):383–389.